Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285214 · ClinicalTrials.gov registry record · Phase 1
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
A Phase 1 study, sponsored by Imbrium Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT06285214: Completed Phase 1 study, sponsored by Imbrium Therapeutics.
NCT06285214 is a Phase 1 study that has completed, run by Imbrium Therapeutics. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06285214, a Phase 1 study, has completed, sponsored by Imbrium Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Primary Outcome
Each evening and morning the subject responded to the question "Please indicate the worst bladder pain/discomfort you have had overnight/over-the-day" using an 11-point numerical rating scale (NRS) that ranges from 0 = "no bladder pain/discomfort" to 10 = "as bad as you can imagine bladder pain/discomfort."
Interventions
- DRUG Placebo
- DRUG V117957
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 1 |
What the finished NCT06285214 record still lists
NCT06285214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06285214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06285214 about?
NCT06285214 is a clinical study titled "Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome". The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
What is the current status of trial NCT06285214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2022-05-26. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT06285214?
The interventions under investigation include: Placebo (DRUG), V117957 (DRUG).
Who is sponsoring clinical trial NCT06285214?
This trial is sponsored by Imbrium Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06285214's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI